You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR LEUKERAN

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for LEUKERAN

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00875667 ↗	A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)	Completed	Celgene	Phase 2	2009-04-30	To evaluate the safety and efficacy of lenalidomide versus investigator choice in patients with relapsed or refractory mantle cell lymphoma.
NCT00875667 ↗	A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)	Completed	Celgene Corporation	Phase 2	2009-04-30	To evaluate the safety and efficacy of lenalidomide versus investigator choice in patients with relapsed or refractory mantle cell lymphoma.
NCT00910910 ↗	Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)	Completed	Celgene	Phase 3	2009-10-13	The purpose of this study is to determine the safety and efficacy of lenalidomide as a first line therapy in treating patients with B-cell Chronic Lymphocytic Leukemia. This study will compare the effects (good and bad) of lenalidomide with chlorambucil.
NCT00910910 ↗	Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)	Completed	Celgene Corporation	Phase 3	2009-10-13	The purpose of this study is to determine the safety and efficacy of lenalidomide as a first line therapy in treating patients with B-cell Chronic Lymphocytic Leukemia. This study will compare the effects (good and bad) of lenalidomide with chlorambucil.
NCT01088048 ↗	Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or	Completed	Gilead Sciences	Phase 1	2010-03-25	The primary objective of the study is to evaluate the safety of idelalisib in combination with an anti-CD20 monoclonal antibody (mAb), a chemotherapeutic agent, a mammalian target of rapamycin (mTOR) inhibitor, a protease inhibitor, an antiangiogenic agent, and/or an immunomodulatory agent in participants with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL).
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for LEUKERAN

Condition Name

Chart
Table

Condition Name for LEUKERAN
Intervention	Trials
Chronic Lymphocytic Leukemia	3
Mantle Cell Lymphoma	2
B-Cell Chronic Lymphocytic Leukemia (B-CLL)	1
Chronic Lymphocytic Leukaemia	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for LEUKERAN
Intervention	Trials
Leukemia, Lymphoid	5
Leukemia, Lymphocytic, Chronic, B-Cell	5
Leukemia	5
Lymphoma, Mantle-Cell	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for LEUKERAN

Trials by Country

Map
Table

Trials by Country for LEUKERAN
Location	Trials
United States	62
United Kingdom	21
Brazil	5
Australia	4
Italy	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for LEUKERAN
Location	Trials
Washington	3
Texas	3
New York	3
Missouri	3
California	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for LEUKERAN

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for LEUKERAN
Clinical Trial Phase	Trials
Phase 3	4
Phase 2	1
Phase 1	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for LEUKERAN
Clinical Trial Phase	Trials
Completed	3
Unknown status	2
Active, not recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LEUKERAN

Sponsor Name

Chart
Table

Sponsor Name for LEUKERAN
Sponsor	Trials
Celgene	2
Celgene Corporation	2
Chugai Pharma USA	1
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for LEUKERAN
Sponsor	Trials
Industry	10
Other	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.